CoChat

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.

Open access

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Background Treatment with antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies has been restricted to metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors. Next-generation sequencing (NGS) allows the assessment in a single analysis of a large number of gene alterations and might provide important predictive and prognostic information.Patients and methods In the CAPRI-GOIM trial, 340 KRAS exon 2 wild-type mCRC patients received first-line FOLFIRI plus cetuximab. Tumor samples (182/340, 53.5%) were assessed by NGS to search for mutations in 22 genes involved in colon cancer.Results Objective responses in the NGS cohort were observed in 104/182 patients [overall response rate (ORR) 57.1%; 95% confidence interval (95% CI) 52% to 66.4%] with a median progression-free survival (mPFS) of 9.8 (95% CI 8.7-11.5) months. NGS analysis was successfully completed in all 182 samples. One or more gene mutations (up to five) were detected in 124/182 (68.1%) tumors within 14/22 genes for a total of 206 mutations. KRAS exon 2 mutations were identified in 29/182 (15.9%) samples, defined as wild type by local laboratory assessment. Frequently mutated genes were: TP53 (39.6%), KRAS exons 3/4 (8.8%), NRAS exons 2/3 (7.1%), PIK3CA exons 9/20 (13.2%), BRAF (8.2%). FOLFIRI plus cetuximab treatment determined ORR of 62.0% (95% CI 55.5% to 74.6%) with mPFS of 11.1 (95% CI 9.2-12.8) months in patients with KRAS and NRAS wild-type tumors. Conversely, ORR was 46.6% (95% CI 39.9-57.5%) with mPFS of 8.9 (95% CI 7.4-9.6) months in patients with KRAS or NRAS mutations. Similarly, the subgroup of patients carrying KRAS, NRAS, BRAF, or PIK3CA mutations showed a worse outcome, although this might be due to a prognostic effect.Conclusions This study demonstrates that NGS analysis in mCRC is feasible, reveals high level of intra and intertumor heterogeneity, and identifies patients that might benefit of FOLFIRI plus cetuximab treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdu230

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 1

  1. Stintzing, 2013, Analisi of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of Folfiri plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients, Eur J Cancer, 49, LBA17

Cited by

See all 116

Metadata

Authors
Ciardiello, F., Normanno, N., Maiello, E., Martinelli, E., Troiani, T., Pisconti, S., Giuliani, F., Barone, C., Cartenì, G., Rachiglio, A. M., Montesarchio, V., Tonini, G., Rizzi, D., Cinieri, S., Bordonaro, R., Febbraro, A., De Vita, F., Orditura, M., Fenizia, F., Lambiase, M., Rinaldi, A., Tatangelo, F., Botti, G., & Colucci, G.
Affiliations
  • University of Campania "Luigi Vanvitelli" (IT)
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
  • Casa Sollievo della Sofferenza (IT)
  • Ospedale SS. Annunziata (IT)
  • Istituto Tumori Bari (IT)
  • Agostino Gemelli University Polyclinic (IT)
  • Ospedale Antonio Cardarelli (IT)
  • Ospedale Monaldi (IT)
  • Università Campus Bio-Medico (IT)
  • Ospedale A. Perrino (IT)
  • Ospedale Garibaldi (IT)
Corresponding author
Ciardiello, F.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2014-09
Volume
25
Issue
9
Pages
1756-1761
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2162247266
Cited by
116
References
17
Citations by year
2025: 1 · 2024: 5 · 2023: 6 · 2022: 9 · 2021: 8 · 2020: 13 · 2019: 9 · 2018: 15 · 2017: 14 · 2016: 13 · 2015: 21 · 2014: 2
FWCI
8.04
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, other-oa)
  • Zenodo (CERN European Organization for Nuclear Research) (other-oa)
Funders
Associazione Italiana per la Ricerca sul Cancro
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
metastatic colorectal cancer, FOLFIRI, cetuximab, anti-EGFR monoclonal antibody, KRAS exon 2 mutation, NRAS mutation, TP53 mutation, PIK3CA mutation, BRAF mutation, next-generation sequencing, predictive biomarkers, first-line therapy, treatment response, progression-free survival, RAS wild-type
MeSH terms
Cetuximab, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Base Sequence, Camptothecin, Leucovorin, Fluorouracil, Humans, Membrane Proteins, Mutation, Proto-Oncogene Proteins, Retrospective Studies, Colorectal Neoplasms, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Sequence Analysis, DNA, Disease-Free Survival, ras Proteins, Phosphatidylinositol 3-Kinases, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, Class I Phosphatidylinositol 3-Kinases, High-Throughput Nucleotide Sequencing, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. https://app.cochat.ai/papers/10.1093/annonc/mdu230
The paper
Ciardiello, F., Normanno, N., Maiello, E., Martinelli, E., Troiani, T., Pisconti, S., Giuliani, F., Barone, C., Cartenì, G., Rachiglio, A. M., Montesarchio, V., Tonini, G., Rizzi, D., Cinieri, S., Bordonaro, R., Febbraro, A., De Vita, F., Orditura, M., Fenizia, F., . . . Colucci, G. (2014). Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Annals of Oncology. https://doi.org/10.1093/annonc/mdu230

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.